Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TOOKAD (padeliporfin) vascular targeted photodynamic therapy for low-grade upper tract urothelial cancer
2024-512322-28-00Phase 3Authorised
- Sponsor
- Steba Biotech
- Start
- Oct 2022
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of padeliporfin VTP in upper tract urothelial carcinoma (UTUC), sponsored by Steba Biotech. Primary endpoints: Complete response in the entire ipsilateral upper urinary tract and Definition of complete response. Planned start Oct 2022; status: authorised.
02
Drugs
padeliporfin VTP
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2024-512322-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512322-28-00.